Program Structure
ATTD-ASIA is a groundbreaking expansion of ATTD – the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes assemble with the aim of sharing knowledge and developing collaborations.
We’re working to provide a Scientific Program filled with the latest therapies for diabetes management!
Faculty and lectures already confirmed for 2025
| Anastasia Albanese-O’Neill | Implementing an early T1D detection pilot center |
| Samita Garg | Obesity and liver – Rationale for new terminology: MASLD/MASH |
| Satish Garg | Use of CGM in T2D: Glucose control and frequency of CGM use |
| Jae Hyeon Kim | Use of CGM in T2D: Cardiovascular autonomic neuropathy in T2D and CGM metrics |
| Noriko Kodani | Advocacy for technology access/ What more is needed in diabetes technology from the patient’s perspective? |
| Vishwanathan Mohan | Diagnosing and intervening in early stages of diabetes T2D: Early medical intervention options |
| Sun-Joon Moon | Precision nutrition guided by CGM in patients with diabetes |
| Revital Nimri | Decision support system in the treatment of people with diabetes |
| Rimei Nishimura | Upcoming use of CGM: CGM based interventions in pre- T2D |
| Sarah Price | Using CGM to better under pre-eclampsia in women with T1D |
| Viral Shah | CGM for people with pre-type 2 diabetes |
| Subhash Wangnoo | Obesity and liver: Treatment options |
| Jee-Hee Yoo | GMi Vs. HbA1c in Asian T1D patients |
| Thomas Danne | CKM is a tool for the majority of insulin-treated people |
| Catarina Limbert | The 12 steps of the Declaration of Lisbon 2024 |
